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Over the past few decades heart transplantation has become the established surgical 
treatment for end-stage heart failure. Transplanted hearts have some limitations 
compared with native hearts; they have blunted physiological responses, intrinsic 
allograft sino-atrial (SA) node dysfunction and allograft denervation related 
hypersensitivity.  As transplanted hearts age, their valves and circulation deteriorate 
more rapidly than native hearts.  Heart recipients often also have transplant associated 
and pre-existing native co-morbidities. (1, 2) 
 
While there are surgical case reports of cardiothoracic interventions (3-6) and 
transcatheter aortic valve replacement (TAVR) procedures (7-11) in post heart 
transplant patients, there is a paucity of anaesthetic management literature for this 
combination of disease and related surgery. In this report we detail the successful 
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anaesthetic management of a high risk heart transplant recipient returning for a 
transfemoral TAVR procedure for severe aortic stenosis. 
 
Case Description  
 
The patient is a 65-year-old Caucasian male who received an orthotopic heart 
transplant in 2002 for ischemic cardiomyopathy. Since then he had been assessed 
regularly by the heart failure team before presenting twelve years post heart transplant 
to the advanced heart failure and cardiac transplant service in late 2014. 
 
On presentation, he was noted to be morbidly obesity (BMI 53 cm
2
/kg) and unable to 
mobilise more than fifty metres on flat ground and was under surveillance for a 
recently diagnosed myeloma.  He also had following co morbidities:  
 
 Stage 3 chronic kidney disease (CKD) with an estimated glomerular filtration rate 
(eGFR) of 37 mls/min, secondary to diabetes and chronic calcineurin inhibitor; 
 orthopnoea, paroxysmal nocturnal dyspnoea (PND) and intermittent ankle oedema; 
 long standing diabetes mellitus type 2 with high insulin requirement, dyslipidemia 
and peripheral neuropathy; 
 a 60 pack year smoking history, obstructive sleep apnoea and non-compliance with 
continuous positive airways pressure (CPAP) therapy; 
 chronic venous insufficiency and mild peripheral vascular disease; and 
 chronic back and hip pain secondary to osteoarthritis.  
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His routine medications included cyclosporine, mycophenolate sodium, frusemide, 
allopurinol, diltiazem, ramipril, aspirin and protophane and insulin injection, 
oxycodone, paracetamol codeine. 
 
His echocardiogram before balloon aortic valvuloplasty (BAV) showed severe 
allograft aortic stenosis with aortic valve (AVA) 0.7 cm
2





velocity 4 meters/sec in setting of moderate left ventricular (LV) dilation,  severely 
depressed left ventricular function with an ejection fraction of 21%, mildly impaired 
right ventricular function and right ventricular systolic pressure (RVSP) of 50 mmHg. 
He was diagnosed with decompensated heart failure, and after optimisation with anti- 
cardiac failure medications he underwent BAV with local anaesthesia and sedation 
technique. (Fig 1A and 1B) 
 
His post BAV echocardiogram showed severe aortic stenosis and moderate aortic 
regurgitation with an AVA of 0.89 cm
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, velocity 4 
meters/sec in the setting of moderate LV dilation, severely depressed left ventricular 
function with a left ventricular ejection fraction of 26%, mildly impaired right 
ventricular function and an RVSP of 68 mmHg.  In keeping with these results his 
symptoms persisted and he was continued on anti-cardiac failure medication and re-
admitted with further decompensated cardiac failure.   
 
Subsequently he underwent coronary angiogram, which was of poor quality due to 
obesity and heavy calcification of the aortic valve and showed diffuse but minor 
coronary artery disease suggesting diffuse allograft vasculopathy with calcified 
ascending aorta.  His pulmonary function tests showed a forced expiratory volume in 
one second (FEV1) of 70% and a diffusing capacity for carbon monoxide (DLCO) of 
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60% with mild airway obstruction and impaired gas transfer.  Further definitive 
treatment was considered possible but conventional surgical aortic valve replacement 
(SAVR) was deemed to be prohibitively high risk in this clinical setting of; 
 
 redo cardiac surgery; 
 previous heart transplant; 
 previously stated comorbidities including a BMI of 53 cm2/kg; 
 a peak aortic gradient of 65 mmHg and a mean gradient of 40 mmHg; 
 severely depressed left ventricular function with an LVEF of 26%; 
 New York Heart Association (NYHA) grade 4 dyspnoea;  
 the potential for poor wound healing due to immunosuppressive treatment; and 
 a predicted surgical mortality by logistic Euroscore of 30%. (12) 
 
With SAVR deemed excess high risk due to increased perioperative morbidity and 
mortality, surgical option   was declined by the surgical team. The patient was 
referred to our multidisciplinary heart transplant team.  The team reviewed the 
available management options including conservative medical management. After 
long deliberation with the patient, he consented for a TAVR procedure.  
 
Pre-procedure aorta-iliac-femoral computer tomography (CT) showed acceptable 
vessel calibre and a feasible TAVR  by  trans-femoral approach. The procedure was 
planned in a multi-disciplinary “pre-procedure TAVR meeting”.  Careful clinical 
allowance was given to the low coronary ostial height and probable need to resize the 
aortic valve (AV), the poor quality of the CT scan secondary to obesity and heavy AV 
calcification and the patient’s inability to tolerate supine positioning due to increasing 
orthopnoea and osteoarthritic back and hip pain.  Considering all these factors general 
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anaesthesia (GA) was included in the clinical plan and 3-D transoesophageal 
echocardiography (TEE) was considered mandatory and unavoidable.  
On the day of the TAVR, the patient received all of his regular medications including 
aspirin 75mg. In addition he received a 300mg loading dose of clopidogrel. Standard 
antibiotics were given for the first three days following the procedure. 
 
The TAVR was performed by a team comprised of interventional cardiologists, an 
echocardiography specialist cardiologist, cardiac anaesthetists and other team 
members in a hybrid theatre with full state of the art facilities at a University Hospital.   
The patient was positioned on head elevating laryngoscopy pillows (13) for comfort 
and to facilitate intubation in a ramped position. In compliance with TAVR standard 
monitoring protocol 5-lead electrocardiography, pulse oximeter, invasive blood 
pressure, capnometry, oesophageal temperature, Bispectral Index™ (BIS) and 
cerebral oxygen monitoring were used. 
Induction of general anaesthesia was performed via a large bore cannula with an 
effect-site target controlled infusion of Propofol titrated to BIS, fentanyl 1 
microgram/kg and muscle relaxant rocuronium bromide 1mg/kg with neuromuscular 
monitoring. Anaesthesia was maintained with oxygen, air and sevoflurane. Fragile 
skin areas were padded and the patient was placed in the supine position to avoid 
excessive pressure on stress points.  In anticipation of a difficult airway and in view of 
active anticoagulation, a C-MAC videolaryngoscopy system was used to decrease 
airway manipulation. The right internal jugular vein was cannulated to insert a 
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temporary pacing wire.  A 3M™ Bair Hugger and body blanket therapy was used to 
preserve patient warmth. 
The authors acknowledge the need for GA and transoesophageal echocardiography 
(TEE) monitoring in hybrid theatre for some TAVR procedures, but consider that the 
risks of general anaesthesia must be balanced against the alternative use of local 
anaesthesia and conscious sedation (LAS) techniques, which offer excellent real time 
neurological monitoring and advantages for some patients. (14-17)   
This patient’s TEE was performed by echocardiologists according to standard 
cardiology protocol for diagnostic and therapeutic interventions.  TEE mid-
oesophageal long axis view (120 degrees) aided correct placement and deployment of 
the TAVR valve.    The retrievable TAVR system, Lotus™ 25 mm valve with bovine 
pericardium leaflets and a frame height of 19 mm was correctly deployed via right 
femoral artery approach under TEE and fluoroscopic guidance.  (Fig 2A and 
2B)Transient trans-gastric TEE views were taken intermittently during non-
interventional periods for real time assessment of left ventricular function, 
hemodynamics and potential complications intra-procedure.   
 
Post-procedurally, coronary artery patency was confirmed by coronary angiography 
and TEE was used to rule out paravalvular leakage and assess prosthetic valve 
position and function.  This included assessing aortic prosthesis hemodynamics, LV 
function and volume status and investigating for any new valvular or regional wall 
motion abnormalities, pericardial effusion and left ventricular outflow tract (LVOT) 
and aortic injuries.   The patient was successfully extubated using the new reversal 
agent sugammadex and neuromuscular monitoring by standard criteria.  The patient 
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was monitored in the recovery room for approximately one hour and then transferred 
to the Cardiac Care Unit for monitoring for the first 48 hours.  
This patient has been followed up in our Cardiology Outpatient clinic over the last 
eighteen months post-TAVR. He reports compliance with his medical treatment and 
clinical follow-up.  His LVEF has increased from 20% to 50% and he currently 
describes NYHA grade 2 dyspnoea.  In summary, after a TAVR to his allograft heart 
he now shows improved ventricular function, clinical performance and functional 
capacity. Written informed consent was later obtained from the patient to publish a 
journal article. 
Discussion 
Cardiac transplantation is now practised all over the world for end stage heart failure 
patients.  The current recipient median life span is two decades or more. Because of 
improvement in surgical and medical management, this subset of patients now live 
long enough to present subsequent surgical and anaesthetic challenges related to their 
aging transplanted heart, pathophysiology and ongoing immunosuppressant treatment. 
(1, 2, 11) 
TAVR is a treatment option for inoperable and prohibitive high-risk surgical patients.  
Although more than 50,000 valves have been implanted by TAVR globally, there are 
only a few case reports of subsequent TAVR in heart transplant recipients, including 
recipients with severely depressed LVEF as in this report. There are several 
publications reporting TAVR outcome trials, follow-up data and clinical registries. 
(18-25)  
It is of note that causes of left ventricular dysfunction in heart transplant patient can 
be multifactorial and include allograft vasculopathy, vascular and cellular rejection, 
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pericarditis, cellular infection and unknown mechanisms. Clinical outcome in severe 
aortic stenosis with left ventricular dysfunction depends on the balance of aortic 
stenosis severity and left ventricle reserve, which is why our patient was more 
symptomatic with a failing left ventricle, excessively high gradient and afterload. The 
overall performance improvement in our patient persisting through the follow up 
period is consistent with that of an SAVR procedure. (26-28) 
Following are some of the important anaesthetic considerations for this patient. 
 Rapid right ventricular pacing was employed before final prosthetic valve 
implantation and hemodynamics were maintained by judicious bolus use of 
direct-acting pressers (ephedrine 3 mg/ml and adrenaline in a low 
concentration of 1 microgram/ml). 
 Intermittent and non-interventional TEE trans-gastric short axis mid papillary 
and mid-cavity views were used to monitor fluid status and contractility.  This 
is because procedurally-concealed bleeding and hypovolemia has been 
reported with this procedure and are known to be catastrophic in hearts with 
blunted physiological responses. (2) 
 The deliberate choice of a new agent, sugammadex, to reverse rocuronium 
bromide in order to avoid a potentially catastrophic response to neostigmine.  
This is because in addition to intrinsic allograft SA node dysfunction of heart 
transplant patients, the allograft denervation related hypersensitivity of both 
the post-ganglionic neurons and the muscarinic myocardial receptors to the 
cholinergic agonist effect of neostigmine is known to have the potential to 
produce severe dysfunction or sinus arrest after neostigmine (anti-
acetylcholinesterase) administration (29,30). 
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 Heart transplant patients require  special consideration of many issues which 
include evaluation of rejection and cardiac allograft vasculopathy (CAV), 
utmost control of infection and maintenance of immunosuppressive agents and 
vigilant use of all drug pharmacokinetic and pharmacodynamic parameters in 
the context of renal impairment. 
Most expert and high volume centres have started practising local anaesthesia and 
sedation techniques for TAVR procedures. There are many advantages to this 
anaesthetic technique, including capacity for neurological monitoring, rapid recovery, 
decreased hospital length of stay and cost efficiencies. As in our complex polymorbid 
patient, anaesthetic technique selection for the TAVR patient is crucial considering 
approximately 20% of LAS cases convert to general anaesthesia due to high vascular 
or procedural complications.  The presence of a cardiac anaesthesiologist throughout 
the procedure is essential irrespective of technique, location and surgical expertise. 
(17) 
 
This case report demonstrates the importance of involving cardiac anaesthesiologists 
from the beginning of the case and during all phases of patient care from pre-
operative evaluation to patient discharge from the operating theatre complex. It 
highlights the essential role of the anaesthesiologist as part of the peri-operative team 
both pre-operatively as team leader, collaborator and patient advocate, and intra-
operatively for the provision of expert clinical vigilance and monitoring.  Due to the 
rapid pace of technological advancement and the acceptance of marginal donors for 
heart transplant, we expect an increase in this subset of patients presenting for 
complex and high risk interventional procedures. 
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In summary, this case report emphasises the importance of teamwork and expertise 
and knowledge from various specialities in the management of a high-risk post-
transplant patient. TAVR is a feasible, safe, suitable and viable therapeutic option in 
heart transplant recipients with multiple risk factors. In the hands of an expert 
proceduralist, TAVR has a high success rate and offers a minimally invasive option 
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Fig 1A: Balloon aortic valvuloplasty (BAV)-fluoroscopic still picture. 




Fig 2A: Lotus™ 26mm valve system deployment with TOE probe on right side of the 
image. 
Fig 2B: TOE mid oesophageal long axis view with Lotus™ Valve in situ. 
 
 
  
 15 
Fig 1A 
 
 
Fig 1B 
 
 
 16 
Fig 2A 
 
 
Fig 2B 
 
